Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Akorn Receives sNDA Approval for Inapsine | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Akorn Receives sNDA Approval for Inapsine

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Akorn, Inc. has received approval for a supplemental new drug application (SNDA) approval for Inapsine injection. Akorn is the NDA holder of this drug product, which has been off the market since 2001 due to compliance issues associated with Akorn’s Decatur manufacturing facility. Akorn recently was awarded a contract for Inapsine from Premier Purchasing Partners, LP, a hospital group purchasing organizations. The award is effective July 1, 2006. Arthur S. Przybyl, Akorn’s president and chief executive officer, stated, “We are pleased to announce this product approval. We expect to launch Inapsine in June 2006.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters